Replimune Group, Inc. (NASDAQ:REPL) Short Interest Up 16.7% in January

Replimune Group, Inc. (NASDAQ:REPL) saw a large growth in short interest in the month of January. As of January 31st, there was short interest totalling 8,470,000 shares, a growth of 16.7% from the January 15th total of 7,260,000 shares. Based on an average daily volume of 885,200 shares, the days-to-cover ratio is presently 9.6 days.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the company. HC Wainwright upped their target price on Replimune Group from $21.00 to $22.00 and gave the stock a “buy” rating in a research report on Thursday. Jefferies Financial Group raised their price objective on shares of Replimune Group from $16.00 to $19.00 and gave the company a “buy” rating in a research note on Wednesday, December 4th. Finally, BMO Capital Markets lifted their price objective on shares of Replimune Group from $18.00 to $27.00 and gave the company an “outperform” rating in a report on Wednesday, January 22nd. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Replimune Group presently has a consensus rating of “Buy” and a consensus price target of $19.29.

Insider Activity

In other Replimune Group news, CEO Sushil Patel sold 10,000 shares of the firm’s stock in a transaction on Monday, December 16th. The shares were sold at an average price of $12.42, for a total value of $124,200.00. Following the completion of the sale, the chief executive officer now directly owns 202,014 shares in the company, valued at approximately $2,509,013.88. This trade represents a 4.72 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 8.80% of the stock is owned by company insiders.

Hedge Funds Weigh In On Replimune Group

Several hedge funds and other institutional investors have recently modified their holdings of the company. Algert Global LLC raised its holdings in shares of Replimune Group by 7.1% during the fourth quarter. Algert Global LLC now owns 45,820 shares of the company’s stock valued at $555,000 after acquiring an additional 3,057 shares in the last quarter. Boxer Capital Management LLC purchased a new position in Replimune Group during the 4th quarter valued at $21,754,000. Jane Street Group LLC lifted its position in shares of Replimune Group by 20.6% in the 4th quarter. Jane Street Group LLC now owns 316,287 shares of the company’s stock worth $3,830,000 after purchasing an additional 54,039 shares during the period. Freestone Grove Partners LP purchased a new position in shares of Replimune Group during the fourth quarter valued at about $140,000. Finally, Northern Trust Corp raised its stake in Replimune Group by 7.3% in the fourth quarter. Northern Trust Corp now owns 589,635 shares of the company’s stock worth $7,140,000 after buying an additional 40,134 shares in the last quarter. 92.53% of the stock is owned by institutional investors.

Replimune Group Stock Down 1.3 %

Shares of NASDAQ REPL traded down $0.19 during trading on Monday, hitting $14.10. The stock had a trading volume of 431,744 shares, compared to its average volume of 790,791. The firm has a fifty day moving average of $12.54 and a two-hundred day moving average of $11.74. The company has a debt-to-equity ratio of 0.18, a current ratio of 10.11 and a quick ratio of 10.11. Replimune Group has a 12 month low of $4.92 and a 12 month high of $17.00. The company has a market capitalization of $964.72 million, a PE ratio of -4.62 and a beta of 1.30.

Replimune Group (NASDAQ:REPL) last issued its earnings results on Wednesday, February 12th. The company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.70) by ($0.09). As a group, equities research analysts forecast that Replimune Group will post -2.88 EPS for the current fiscal year.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.